Navigation Links
PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
Date:3/21/2012

OXFORD, England, March 21, 2012 /PRNewswire/ --

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index's largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Francesco De Rubertis of Index Ventures, Dr Moncef Slaoui, Chairman of R&D at GSK and Dr Paul Stoffels, Worldwide Chairman of Johnson & Johnson Pharmaceuticals describe how the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund.

Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net), containing over 43,000 deal records, and our extensive business relationship network and our outstanding success in M&A trans
'/>"/>

SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
2. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
3. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
4. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
7. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
8. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
9. In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
10. Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues
11. HIKMA - 2008 Preliminary Results Interview With CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... BEIJING, May 1 Sinovac Biotech Ltd. (NYSE Amex: ... in China, today announced that it has filed its Annual ... Commission for the year ended December 31, 2008 on May ... now available on the Company,s website under the investor relations ...
... of $79.7 Million, Increase of 29% over First Quarter 2008- ... per Diluted Share, Increases of 14% and 20% over First ... Therapeutics Corporation (Nasdaq: UTHR ) today announced its ... Total revenues for the first quarter of 2009 were ...
... Earnings Conference Call to be Held on May 15, ... / 8:00 pm (Beijing/Shanghai/Hong Kong)SHANGHAI, May 1 /PRNewswire-Asia/ -- ... a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... today announced that it will release financial results for ...
Cached Biology Technology:Sinovac Biotech Ltd. Files Annual Report on Form 20-F 2United Therapeutics Reports First Quarter 2009 Financial Results 2United Therapeutics Reports First Quarter 2009 Financial Results 3United Therapeutics Reports First Quarter 2009 Financial Results 4United Therapeutics Reports First Quarter 2009 Financial Results 5United Therapeutics Reports First Quarter 2009 Financial Results 6United Therapeutics Reports First Quarter 2009 Financial Results 7WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... A - a potential agent of biological warfare and one ... able to sneak into cells. , The finding is ... paralytic illness caused by the toxin more commonly known as ... alleviate many medical problems, the recent work could help to ...
... found a common genetic variation in an immune system ... psoriasis ?a disfiguring inflammatory skin disease. , Named PSORS1 ... first genetic determinant of psoriasis to be definitively identified ... to new, more effective treatments for psoriasis without the ...
... that appear to play a significant role in the ... ability to form clots following an injury. They also ... may contribute to certain forms of leukemia. , "Basically, ... are turned off in normal platelet development, but turned ...
Cached Biology News:Scientists reveal how deadly toxin hijacks cells 2U-M scientists identify major psoriasis susceptibility gene 2U-M scientists identify major psoriasis susceptibility gene 3U-M scientists identify major psoriasis susceptibility gene 4MiRNA fingerprint identified in platelet formation 2
... Source: Streptomycin verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder ... pH (10 units/ml): 4.5 to 6.0 Loss On Drying: less ... equal to 0.1% Bleomycin Content: A 2 : 55 - ... B 2 : greater than or equal to 90% B ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of ... rabbits, monkeys and humans. 8-iso PGF2α ... lipid peroxidation. In both humans and ... primarily to metabolites having 2 or ...
Biology Products: